SNPX vs. JAN, CARA, LGVN, IBIO, APM, ALTS, INDP, PMCB, UNCY, and EDSA
Should you be buying Synaptogenix stock or one of its competitors? The main competitors of Synaptogenix include JanOne (JAN), Cara Therapeutics (CARA), Longeveron (LGVN), iBio (IBIO), Aptorum Group (APM), Janone (ALTS), Indaptus Therapeutics (INDP), PharmaCyte Biotech (PMCB), Unicycive Therapeutics (UNCY), and Edesa Biotech (EDSA). These companies are all part of the "pharmaceutical products" industry.
JanOne (NASDAQ:JAN) and Synaptogenix (NASDAQ:SNPX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, community ranking, risk, institutional ownership and earnings.
In the previous week, Synaptogenix had 1 more articles in the media than JanOne. MarketBeat recorded 2 mentions for Synaptogenix and 1 mentions for JanOne. Synaptogenix's average media sentiment score of 1.89 beat JanOne's score of 0.56 indicating that JanOne is being referred to more favorably in the media.
JanOne has a beta of 2.16, suggesting that its stock price is 116% more volatile than the S&P 500. Comparatively, Synaptogenix has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500.
Synaptogenix has a consensus target price of $14.00, indicating a potential upside of 229.41%.
Synaptogenix has lower revenue, but higher earnings than JanOne.
Synaptogenix received 2 more outperform votes than JanOne when rated by MarketBeat users.
JanOne's return on equity of -18.51% beat Synaptogenix's return on equity.
6.3% of JanOne shares are held by institutional investors. Comparatively, 10.3% of Synaptogenix shares are held by institutional investors. 3.0% of JanOne shares are held by insiders. Comparatively, 4.3% of Synaptogenix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Synaptogenix beats JanOne on 8 of the 11 factors compared between the two stocks.
Get Synaptogenix News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNPX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Synaptogenix Competitors List
Related Companies and Tools
